

LYONBIOPOLE, MABDESIGN AND BIOASTER COLLABORATE TO STRENGTHEN THE ATTRACTIVENESS OF THE AURA REGION ON INFECTIOUS DISEASES AND IMMUNOTHERAPY

I4ID 2019, resulting from the fusion of the I4ID congress dedicated to immunotherapy organized by MabDesign – association aiming to structure and support the French industrial sector of immunotherapy – and BIOASTER – technological research institute specialized in microbiology and infectiology – and the Nosocomial Infections Days organized by Lyonbiopole, the healthcare – cluster of the Auvergne-Rhône-Alpes region, will be held on December 4 and 5 2019 at the Ecole Normale Supérieure de Lyon. These three emblematic health stakeholders bring together for two days experts from around the world to combine approaches and strengths to innovate in the fields of infectious diseases and immunotherapy.



Through the organization of this congress – in partnership with Sanofi, Boehringer Ingelheim, bioMérieux, GSK, PerkinElmer, Proteigene, Transgene and with the institutional support from the Auvergne-Rhône-Alpes Region and the Lyon Metropolis – **the Auvergne-Rhône-Alpes region, world-renowned in the field of infectious diseases and immunotherapy, will be the epicentre for rich exchanges on research in these fields.**

During these two days, pharmaceutical companies, research laboratories, clinicians, service providers and technology developers will be able to **discuss the development of innovative solutions for the prevention and treatment of infectious diseases.** Half of the speakers at this international congress are regional experts, members of Lyonbiopôle, with a good mix of academics and industrials: these include INSA, INRA, CIRI, bioMérieux, Boehringer Ingelheim, Sanofi Pasteur, Evotec, Axoscience, BiofilmControl, Nosopharm, Molsid, Altrabio and SigniaTherapeutics among others.

The I4ID speakers, 40% from abroad, (from the Netherlands, England, Austria, Sweden, the United States, Belgium, Germany, Finland and Portugal), will focus on the latest advances in the field while laboratories and start-ups will present the new approaches and innovations in the fight against these pathologies. The various approaches of fighting infectious diseases will be discussed: immunotherapies, new antimicrobials, microbiota, vaccines, diagnostic and monitoring tools...

The goal? Highlight synergies and transdisciplinary approaches.

THE HIGHLIGHTS OF THIS CONGRESS

- **Opening lecture by Mr. Serge Weinberg, Chairman of the Board of Directors of Sanofi**
- **Plenary sessions of high scientific level** covering the latest developments and the most innovative projects in the following areas:
 - * **Innovative therapeutic approaches** to fight infectious diseases
 - * **Detection, diagnosis and biomarkers** – fast, efficient and robust new strategies
 - * **Monitoring, epidemiology and control** – management and monitoring of infectious diseases
- **Pitches** of innovative companies and academic laboratories
- **An exhibition hall** to showcase the latest innovations
- **A B2B platform** to facilitate meetings between all stakeholders

ABOUT LYONBIOPOLE

As a French cluster, Lyonbiopole is the gateway to healthcare innovation in Auvergne-Rhône-Alpes. It aims at supporting ambitious projects and innovative companies in the healthcare & life sciences' sector. It encourages innovators to develop new technologies, products and services toward a more personalized medicine and better treatments for patients. The cluster's strategic missions are focused around:

- promoting the emergence of innovative R&D collaborative projects;
- supporting SME in areas such as strategic partnerships, access to private investors, expertise and training;
- fostering SME Internationalization and the cluster's position at the European and International levels;
- offering access to high-level facilities dedicated to life sciences companies;
- promoting members and healthcare ecosystem.

Lyonbiopole currently has 226 members, including major players (Sanofi Pasteur, bioMérieux, Boehringer Ingelheim, Becton Dickinson, Merck, Medtronic, Roche Diagnostics, etc.), a large network of academic & clinical research labs and a vibrant ecosystem of innovative start-ups & SMEs. Lyonbiopole received the European cluster excellence "Gold Label" by ECEI for 2nd time in 2017. The cluster is part of different European initiatives such as bioXclusters, MAGIA, S3martMed and EIT Helath.

For more information: www.lyonbiopole.com

MEDIA CONTACTS

T : 04 78 37 34 64

Laura Ducros – laura@monet-rp.com

Mélanie Da Rui-Pons – mr@monet-rp.com

ABOUT MABDESIGN

MABDESIGN is a French association of the immunotherapy industrial sector.

MabDesign is a national association, created in November 2014, whose aim is to support, structure, federate and increase the visibility of the industrial immunotherapy sector, encourage exchanges and stimulate innovation.

MabDesign has created a national directory of immunotherapy actors, which makes it possible to identify online the know-how available in France. Several times a year, MabDesign organizes high-level national or international scientific events, in collaboration with key actors in the ecosystem to promote innovation. MabDesign also offers specialized and innovative continuing professional training solutions to enable companies to adapt their skills to the latest knowledge in immunotherapy. Finally, MabDesign offers its members a wide range of services to help them optimize their positioning, protect and improve their innovations and conquer new international markets.

Operational since September 2015, MabDesign currently has more than 160 member companies, including pharmaceutical and biotechnology companies, service providers, training organizations and high-tech equipment suppliers.

For more information: www.mabdesign.fr | LinkedIn MabDesign | contact@mabdesign.fr

Press contact : ana-sofia.antunes@mabdesign.fr

ABOUT BIOASTER

BIOASTER - created in 2012 - is a TRI, Technology Research Institute, specialized in microbiology and infectiology. BIOASTER conceives, develops and uses transformative technological innovations to meet the needs of industries. Through public/private collaborative projects, it contributes to accelerating the development of high value-added medical and nutritional solutions for human and animal health. BIOASTER is involved in four areas of application:

- Antimicrobials: Fighting antimicrobial resistance
- Vaccines: improving vaccine safety and efficiency
- Microbiota: taking full advantage of human and animal microbiota
- Diagnosis: Early diagnosis of infections at the patient's bedside

KEY FIGURES

- 2450m2 of BSL 2 & 3 laboratories (LYON & PARIS)
- 100+ collaborators, 80% of whom are scientific experts, 17 different citizenships
- 66 projects, including 27 with private partners, 29 with public partners and 10 international and European projects.

www.bioaster.org / Press contact : olivier.charzat@bioaster.org